Remove special-reports
article thumbnail

Vial2Bag Advanced® 20mm Admixture Device Special Report #2

Progressive Medical

Vial2Bag Advanced® 20mm Admixture Device: Waste Reduction in IV Distribution Large-scale drug waste is an ongoing problem in health care […] The post Vial2Bag Advanced® 20mm Admixture Device Special Report #2 appeared first on Progressive Medical, Inc.

article thumbnail

Vial2Bag Advanced® 20mm Admixture Device Special Report

Progressive Medical

Vial2Bag Advanced® 20mm Admixture Device: Cost Reduction and Operational Efficiency in IV Medication Distribution In recent years, hospital administrators involved […] The post Vial2Bag Advanced® 20mm Admixture Device Special Report appeared first on Progressive Medical, Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

'The Top Line': A look at pharma revenue rankings

Fierce Pharma

Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Staff Writer Kevin Dunleavy are diving into our annual top pharma companies by revenue special report.

Pharma 130
article thumbnail

'The Top Line': Fiercest Women in Life Sciences, meet the Fierce 50

Fierce Pharma

In this episode of "The Top Line," we're highlighting the remarkable women featured in our annual Fiercest Women in Life Sciences special report. | In this episode of "The Top Line," we're highlighting the remarkable women featured in our annual Fiercest Women in Life Sciences special report.

article thumbnail

How to Stay Competitive in the Evolving State of Martech

To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and promote omnichannel marketing.

article thumbnail

'The Top Line': A closer look at the bounty of new drug approvals in 2023

Fierce Pharma

At Fierce Pharma, the arrival of a new year is synonymous with the release of our annual special report on drug approvals. | At Fierce Pharma, the arrival of a new year is synonymous with the release of our annual special report on drug approvals.

article thumbnail

ICER weighs in on Medicare price negotiations with new appraisals of BMS' Eliquis, J&J's Xarelto

Fierce Pharma

ICER submitted a special report to CMS weighing evidence on Bristol Myers Squibb and Pfizer’s Eliquis and Bayer and Johnson & Johnson’s Xarelto to treat nonvalvular atrial fibrillation (NVAF), the condition where both drugs garner most of their prescriptions. As a new age of price negotiations dawns in the U.S.,